Analysis
Cerebras Systems CEO Andrew Feldman told TechCrunch Disrupt 2026 that the AI industry's doomsday warnings are drowning out its potential benefits, arguing some AI leaders "maybe shouldn't be allowed to talk in public" given how often their warnings dominate coverage over the technology's upside, TechCrunch reported.
Feldman's comments respond to a summer and fall of increasingly public AI-safety alarm, including a September 2026 case of an Anthropic researcher who quit while warning that self-improving AI systems could soon escape meaningful human control -- a concern Pulse covered separately in its report on Anthropic's self-replication warning. The debate has become mainstream enough that a recent "Saturday Night Live" sketch parodied Anthropic CEO Dario Amodei with a fictional line: "We do not condone what we are doing."
The case Feldman is making
Feldman argues every powerful technology carries dual-use risk and reward together -- "I think you can't make one and not have the other," he said -- and that the right response is "reasonable" regulation rather than public alarm. He pointed to AI's potential to help cure diseases, saying he wants a future where children "never meet anybody who dies of cancer," and argued the data-center industry has hurt its own image by failing to engage local communities the way the oil and gas industry historically has.
Cerebras, which competes with Nvidia in AI training and inference chips, counts OpenAI, Figma, Block, pharmaceutical company GSK and Lovable among its customers -- a list that gives Feldman's framing real commercial weight rather than pure punditry. Cerebras went public earlier in 2026, and Pulse has since covered its second-quarter earnings, where the company's guidance swings became a live test of investor appetite for AI-infrastructure volatility.
Feldman's remarks don't resolve the underlying safety debate so much as stake out a competing public-relations position -- one that chip and infrastructure vendors with the most to lose from a slowdown have strong incentive to take. Worth noting: Feldman did not name the researchers or labs he believes should talk less, leaving open whether he means direct competitors or allies making him uncomfortable.